829 related articles for article (PubMed ID: 22773826)
1. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover.
Clarke CA; Keegan TH; Yang J; Press DJ; Kurian AW; Patel AH; Lacey JV
J Natl Cancer Inst; 2012 Jul; 104(14):1094-101. PubMed ID: 22773826
[TBL] [Abstract][Full Text] [Related]
2. Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State.
Kohler BA; Sherman RL; Howlader N; Jemal A; Ryerson AB; Henry KA; Boscoe FP; Cronin KA; Lake A; Noone AM; Henley SJ; Eheman CR; Anderson RN; Penberthy L
J Natl Cancer Inst; 2015 Jun; 107(6):djv048. PubMed ID: 25825511
[TBL] [Abstract][Full Text] [Related]
3. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
[TBL] [Abstract][Full Text] [Related]
4. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups.
Kurian AW; Fish K; Shema SJ; Clarke CA
Breast Cancer Res; 2010; 12(6):R99. PubMed ID: 21092082
[TBL] [Abstract][Full Text] [Related]
5. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status.
Howlader N; Altekruse SF; Li CI; Chen VW; Clarke CA; Ries LA; Cronin KA
J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24777111
[TBL] [Abstract][Full Text] [Related]
6. Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status.
Ma H; Lu Y; Malone KE; Marchbanks PA; Deapen DM; Spirtas R; Burkman RT; Strom BL; McDonald JA; Folger SG; Simon MS; Sullivan-Halley J; Press MF; Bernstein L
BMC Cancer; 2013 May; 13():225. PubMed ID: 23642215
[TBL] [Abstract][Full Text] [Related]
7. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
[TBL] [Abstract][Full Text] [Related]
8. Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ.
Liu Y; West R; Weber JD; Colditz GA
Cancer; 2019 Sep; 125(18):3225-3233. PubMed ID: 31120565
[TBL] [Abstract][Full Text] [Related]
9. Disparities in the risk of the ER/PR/HER2 breast cancer subtypes among Asian Americans in California.
Parise C; Caggiano V
Cancer Epidemiol; 2014 Oct; 38(5):556-62. PubMed ID: 25172158
[TBL] [Abstract][Full Text] [Related]
10. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA.
Lund MJ; Trivers KF; Porter PL; Coates RJ; Leyland-Jones B; Brawley OW; Flagg EW; O'Regan RM; Gabram SG; Eley JW
Breast Cancer Res Treat; 2009 Jan; 113(2):357-70. PubMed ID: 18324472
[TBL] [Abstract][Full Text] [Related]
11. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: a population-based study and first report.
Lund MJ; Butler EN; Hair BY; Ward KC; Andrews JH; Oprea-Ilies G; Bayakly AR; O'Regan RM; Vertino PM; Eley JW
Cancer; 2010 Jun; 116(11):2549-59. PubMed ID: 20336785
[TBL] [Abstract][Full Text] [Related]
12. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004.
Brown M; Tsodikov A; Bauer KR; Parise CA; Caggiano V
Cancer; 2008 Feb; 112(4):737-47. PubMed ID: 18189290
[TBL] [Abstract][Full Text] [Related]
13. Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study.
John EM; Koo J; Phipps AI; Longacre TA; Kurian AW; Ingles SA; Wu AH; Hines LM
Breast Cancer Res; 2024 May; 26(1):88. PubMed ID: 38822357
[TBL] [Abstract][Full Text] [Related]
14. Relationship of established risk factors with breast cancer subtypes.
McCarthy AM; Friebel-Klingner T; Ehsan S; He W; Welch M; Chen J; Kontos D; Domchek SM; Conant EF; Semine A; Hughes K; Bardia A; Lehman C; Armstrong K
Cancer Med; 2021 Sep; 10(18):6456-6467. PubMed ID: 34464510
[TBL] [Abstract][Full Text] [Related]
15. Racial comparison of receptor-defined breast cancer in Southern African women: subtype prevalence and age-incidence analysis of nationwide cancer registry data.
Dickens C; Duarte R; Zietsman A; Cubasch H; Kellett P; Schüz J; Kielkowski D; McCormack V
Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2311-21. PubMed ID: 25143359
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.
Parise CA; Bauer KR; Brown MM; Caggiano V
Breast J; 2009; 15(6):593-602. PubMed ID: 19764994
[TBL] [Abstract][Full Text] [Related]
17. Recent trends in breast cancer among younger women in the United States.
Brinton LA; Sherman ME; Carreon JD; Anderson WF
J Natl Cancer Inst; 2008 Nov; 100(22):1643-8. PubMed ID: 19001605
[TBL] [Abstract][Full Text] [Related]
18. Recent breast cancer trends among Asian/Pacific Islander, Hispanic, and African-American women in the US: changes by tumor subtype.
Hausauer AK; Keegan TH; Chang ET; Clarke CA
Breast Cancer Res; 2007; 9(6):R90. PubMed ID: 18162138
[TBL] [Abstract][Full Text] [Related]
19. Reproductive Factors and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer Among Multiethnic Women.
Chen L; Li CI; Tang MT; Porter P; Hill DA; Wiggins CL; Cook LS
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1297-304. PubMed ID: 27307466
[TBL] [Abstract][Full Text] [Related]
20. Racial disparities in breast cancer diagnosis and treatment by hormone receptor and HER2 status.
Chen L; Li CI
Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1666-72. PubMed ID: 26464428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
